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Abstract
Human immunodeficiency virus-1 (HIV-1) viral infectivity factor (Vif) is essential for viral replication because of its ability to
eliminate the host’s antiviral response to HIV-1 that is mediated by the APOBEC3 family of cellular cytidine deaminases. Vif
targets these proteins, including APOBEC3G, for polyubiquitination and subsequent proteasome-mediated degradation via
the formation of a Cullin5-ElonginB/C-based E3 ubiquitin ligase. Determining how the cellular components of this E3 ligase
complex interact with Vif is critical to the intelligent design of new antiviral drugs. However, structural studies of Vif, both
alone and in complex with cellular partners, have been hampered by an inability to express soluble full-length Vif protein.
Here we demonstrate that a newly identified host regulator of Vif, core-binding factor-beta (CBFb), interacts directly with Vif,
including various isoforms and a truncated form of this regulator. In addition, carboxyl-terminal truncations of Vif lacking
the BC-box and cullin box motifs were sufficient for CBFb interaction. Furthermore, association of Vif with CBFb, alone or in
combination with Elongin B/C (EloB/C), greatly increased the solubility of full-length Vif. Finally, a stable complex containing
Vif-CBFb-EloB/C was purified in large quantity and shown to bind purified Cullin5 (Cul5). This efficient strategy for purifying
Vif-Cul5-CBFb-EloB/C complexes will facilitate future structural and biochemical studies of Vif function and may provide the
basis for useful screening approaches for identifying novel anti-HIV drug candidates.
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Introduction
Virion (orviral)infectivityfactor(Vif),a 23-kDa accessory protein
of human immunodeficiency virus type 1 (HIV-1) and many related
lentiviruses, is essential for viral replication. Vif inactivates the
antiretroviral activity of the host APOBEC3 cytidine deaminases,
including APOBEC3G (A3G) and A3F [1,2,3,4,5,6]. A3G [7] and
related human APOBEC3 proteins are potent inhibitors of HIV-1
in the absence of viral Vif. A3G can be packaged into HIV-1
particles through the nucleocapsid RNA-binding domain (NC) of
viral Gag [8,9,10,11,12,13,14,15,16], along with a contribution
from viral or cellular RNAs [8,9,10,11,12,13,14,15,16,17,18]. A3G
viral packaging leads to the induction of C-to-U mutations in the
minus-strand viral DNA during reverse transcription within newly
infected cells [19,20,21,22,23,24,25]. In addition, virion-packaged
APOBEC3 proteins can reduce the accumulation of viral DNA
[26,27,28,29,30,31,32,33] and the formation of proviral DNA
[23,28,29,34].
Vif induces polyubiquitination and degradation of multiple
APOBEC3 molecules [35,36,37,38,39,40,41,42]. Specifically, Vif
acts as a substrate receptor for specific APOBEC3 proteins, while
also recruiting a cullin5-RING (CRL5) ubiquitin ligase complex
composedofCul5,ElonginB (EloB),ElonginC(EloC), and a RING-
box protein [35] through a highly conserved virus-specific BC-box
motif [36,43] and a HCCH motif [44,45,46,47]. Various Vif motifs
have been found to participate in the interaction of HIV-1 Vif with
diverse substrates [6,38,48,49,50,51,52,53,54,55,56,57,58].
To determine how Vif hijacks the CRL5 E3 ligase in order to
degrade the antiviral proteins A3G and A3F, researchers have
sought to characterize Vif-E3 ligase-related complexes, such as
EloB/C with a Vif C-terminal fragment (residues 139–176) [59],
synthetic Vif C-terminal domains [60,61,62], and EloB/C-Vif-Cul5
interactions [63,64]. These studies have identified important motifs
responsible for the interaction between Vif, EloB/C and Cul5.
However, structural and functional analyses of full-length Vif
continue to be limited by difficulty in obtaining suitable quantities
of soluble full-length Vif protein [65,66,67,68]. In an attempt to
overcome this limitation, a denaturing/refolding method has been
developed for purifying soluble recombinant Vif [65,68,69,70].
Although this approach produced large quantities of full-length
protein, the protein formed high molecular weight aggregates in
solution [65,68,69,70]. Vif’s tendency to aggregate and become
insoluble has limited its structural characterization and functional
analysis [63].
Co-expression of binding partners has been shown to improve
the solubility and stability of various proteins [71]. Here, we report
PLoS ONE | www.plosone.org 1 March 2012 | Volume 7 | Issue 3 | e33495that co-expression of Vif with EloB/C and CBFb, a newly
identified regulator of HIV-1 Vif function [72,73,74,75], can
greatly improve the solubility of full-length Vif. We also
demonstrate that C-terminal truncated Vif mutants of up to 140
amino acids can still interact with CBFb. Purified amino-terminal
domain of Cul5 (residues 1–393) readily interacts with this
complex. Vif-CBFb-EloB/C-Cul5 complexes purified by our
strategy were not prone to aggregate and can therefore facilitate
future structural and biochemical studies of Vif function.
Materials and Methods
Cloning, expression, and purification
Full-length Vif192 in the pET21 vector was a gift from Drs.
Rahul M. Kohli and James T. Stivers. Truncated Vif176 and
Vif140 were cloned into pET21 vector. Elongin B and Elongin C
(residues 17 to 112) in the pACYC-Duet plasmid were a gift from
Alex Bullock (University of Oxford, Oxford, United Kingdom).
Mouse CBFb (residues 1–187) cDNA were a gift from Nancy A.
Speck (University of Pennsylvania). CBFb isoform 1 (residues 1–
187) from mouse, CBFb isoform 2 (residues 1–182) and truncated
CBFb (residues 1–140) from human were cloned into pRSF-Duet.
For expression, the plasmids were transformed into Escherichia coli
BL21(DE3) cells. The constructs used in this study are summarized
in Fig. 1. The proteins were over-expressed overnight at 16uCb y
induction with 0.1 mM isopropyl-D-thiogalactopyranoside (IPTG).
Harvested cells were lysed in 20 mM Tris-HCl, pH 8.0, with
150 mM NaCl and then clarified by sonication and centrifugation
at 13,000 g for 30 min. For solubility analysis, the supernatant was
removed and the pellet resuspended to the original volume. For
nickel affinity purification, the supernatant was transferred to Ni-
NTA beads (Invitrogen), and the flowthrough was loaded onto Ni-
NTA beads for two more passages. After washing with20 mMTris-
HCl, pH 8.0, with 150 mM NaCl and 40 mM imidazole, the
protein complex was eluted with 20 mM Tris-HCl, pH 8.0, with
150 mM NaCl and 400 mM imidazole. Gel filtration and anion
exchange were utilized to remove trace contamination. Cul5-NTD
(residues 1 to 393 with two point mutations, V341R and L345D) in
the pGEX-6p-1 vector was expressed in E. coli BL21(DE3) cells
overnight at 16uC by inductionwith 0.1 mM IPTG. Harvested cells
were lysed by sonication in 20 mM Tris-HCl, pH 8.0, with
150 mM NaCl, then clarified by centrifugation at 13,000 g for
30 min. The supernatant was transferred to glutathione-Sepharose
4B beads (GE Healthcare) for glutathione S-transferase (GST)
affinity chromatography. The GST tag was then removed using
Prescission protease. Gel filtration chromatography was utilized for
further purification.
Gel filtration chromatography
Each Vif complex and Cul5 sample was concentrated to 300 ml
and loaded onto a Superdex 200 (10/300 GL) column (GE
Healthcare) with a 500-ml loop and run at a flow rate of 0.3 ml per
min; the column was calibrated using vitamin B12 (1,370 Da),
myoglobin (17,000 Da), ovalbumin (44,000 Da), gamma globulin
(158,000 Da), and thyroglobulin (670,000 Da) as standards. The
gel filtration buffer for Vif-CBFb was composed of 20 mM Tris-
HCl pH 8.0, with 150 mM NaCl and 10% glycerol. The gel
filtration buffer for Vif-CBFb-EloB/C, Vif- CBFb-EloB/C-Cul5,
and Cul5 was 20 mM Tris-HCl, pH 8.0, with150 mM NaCl.
Pull-down analysis of the Vif-CBFb interaction
For pull-down experiments analyzing the interactions between
Vif and CBFb, supernatant was incubated on Ni-NTA agarose for
30 min at 4uC. After incubation, the reaction mixtures were
washed 10 times with 1 ml lysis buffer. The samples were then
analyzed by SDS-PAGE and visualized with Coomassie staining
or by immunblotting with specific antibodies.
Immunoblot analysis
Proteins were separated by SDS-PAGE, then transferred to
nitrocellulose membranes (Bio-Rad). After blocking with PBS-
buffered saline-Tween 20 containing 5% BSA for 1 h at room
temperature, membranes were incubated with a specific antibody
overnight at 4uC. After three washes with PBS-buffered saline-
Tween 20, the membranes were stained with an alkaline
phosphatase-conjugated secondary antibody (1:5,000, Sigma) for
Figure 1. Constructs used in this study. The vectors and their antibiotic resistance are given, followed by a diagram of the construct: Amp
+,
ampicillin; Kana
+, kanamycin; and Cl
+, chloramphenicol. Elongins B and C (EloB/C) are in a single vector (pACYC-Duet) regulated by dual promoters.
The Precission protease sequence site in glutathione S-transferase (GST) and Cul5 are indicated.
doi:10.1371/journal.pone.0033495.g001
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saline-Tween 20, the membranes were reacted with 5-bromo-4-
chloro-39-indolylphosphate (BCIP) and nitro-blue tetrazolium
(NBT) substrate (Sigma). The antibodies used in this study were
specific for: Vif (the AIDS Research Reagents Program, Catalog
#2221), CBFb (Abcam, Catalog ab11921), EloB (Santa Cruz
Biotechnology, Inc, Catalog sc-11447), EloC (BD Transduction
Laboratories, Catalog 610760), Alkaline Phosphatase-conjugated
secondary mouse and rabbit (Jackson Immunoresearch, Catalog
111-055-045 and 115-055-003).
Results
CBFb co-expression improves the solubility of Vif
To identify strategies that could result in the expression of large
quantities of soluble full-length Vif recombinant proteins, we
constructed various prokaryotic expression vectors for HIV-1 Vif
and its co-factors (Fig. 1). Recombinant Vif protein (residues 1–
192) was efficiently expressed in E. coli BL21(DE3) but remained
predominantly insoluble as indicated by Coomassie staining
(Fig. 2A, lanes 1–3). The Vif protein was also identified by
immunoblotting using a Vif-specific antibody (Fig. 2B, lanes 1–3).
Co-expression with EloB/C improved the solubility of Vif, but
only to a limited extent (Fig. 2A and B, lanes 4–6). When Vif was
co-expressed with CBFb140-His (residues 1–140 of CBFb with six
histidine residues at the N-terminus), the solubility of Vif improved
significantly (Fig. 2A and B, lanes 7–9). Approximately 67% of the
total Vif protein became soluble in the presence of CBFb140-His
(Fig. 2C). Expressing CBFb and EloB/C together further
enhanced the solubility of Vif (Fig. 2A and B, lanes 10–12). When
Vif was co-expressed with CBFb and EloB/C, .90% of the Vif
proteins became soluble (Fig. 2C).
CBFb interacts with Vif
The ability of CBFb140-His to increase the solubility of Vif
suggests that there is an interaction between Vif and CBFb140-
His. To determine whether Vif and CBFb could interact directly,
we attempted to co-precipitate Vif with CBFb140-His and found
Figure 2. Soluble Vif protein was obtained by co-expression with CBFb and EloB/C. Vif was untagged, while CBFb was tagged with 6X His
residues at the N-terminus. (A) Solubility of Vif alone and of co-expressed Vif-EloB/C, Vif-CBFb, and Vif-CBFb-EloB/C. Tot, total lysate; S, supernatant; P,
pellet; CBB, Coomassie staining. (B) Fractions in (A) were checked by Immunoblotting (IB) using protein-specific antibodies. (C) Quantification of Vif
protein by immunoblotting in (B).
doi:10.1371/journal.pone.0033495.g002
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PLoS ONE | www.plosone.org 3 March 2012 | Volume 7 | Issue 3 | e33495Figure 3. CBFb interacts with Vif via its N-terminal domain. (A) Sequence alignment of CBFb isoforms (CBFb187 or CBFb182) and truncated
CBFb140. The N-terminus is omitted. (B), (C), (D) Vif was pulled down by His-tagged CBFb: CBFb140 (B), CBFb187 (C), or CBFb182 (D). Supernatant
from the cell lysates was used as the input sample. Both input and pull-down samples were checked by SDS-PAGE, followed by Coomassie staining or
immunoblotting.
doi:10.1371/journal.pone.0033495.g003
Figure 4. Vif-CBFb-EloB/C forms a homogenous monomeric complex. (A) Gel filtration profile of Vif-CBFb complexes on Superdex 200 (GE
Healthcare). The elution volume (Ve) and corresponding molecular size (MW, calculated using protein standards) are indicated by arrows. (B) SDS-
PAGE and Coomassie staining of Vif-CBFb complexes from the peak fractions in (A). (C) Gel filtration profile of Vif-CBFb-Elo B/C complexes on
Superdex 200. The theoretical calculated molecular size of the monomeric Vif-CBFb-EloB/C was ,65 kDa. (D) SDS-PAGE and Coomassie staining of
Vif-CBFb-EloB/C complexes from the peak fraction in (C). (E) Purified Vif-CBFb187-EloB/C complexes.
doi:10.1371/journal.pone.0033495.g004
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the CBFb140-His on a nickel column (Fig. 3B, lane 2). The
presence of Vif and CBFb140-His in the soluble input fraction and
the co-precipitated samples was confirmed by immunoblotting
using a Vif- or CBFb-specific antibody (Fig. 3B).
There are two major CBFb isoforms that are highly conserved
in mammals ([76,77]: Isoform1 has 182 amino acids, while isoform
2 has a 187 amino acid sequence that is generated by alternative
splicing. The two isoforms differ in the last 22 amino acids
(Fig. 3A). Human and mouse CBFb differ by two amino acids (42
A/T and 117 Q/H). Next, we asked whether the natural isoforms
of CBFb could interact with Vif and found that an interaction did
indeed occur between HIV-1 Vif and isoform 1 CBFb182 (Fig. 3C)
as well as isoform 2 CBFb187 (Fig. 3D) in co-precipitation
experiments. To our knowledge, this is the first reported evidence
of a direct interaction between HIV-1 Vif and various forms of
CBFb, in vitro. Our data also indicate that amino acids 1–140 of
CBFb are sufficient for HIV-1 Vif binding.
Purified Vif-CBFb-EloB/C proteins form a stable
monomeric complex
Soluble Vif and CBFb140 complexes were purified by nickel
affinity chromatography and analyzed by gel filtration using a
Superdex200 10/300 GL size exclusion column. Gel filtration
analysis (Fig. 4A) suggested that Vif and CBFb140 formed a large
aggregated complex of approximately 1000 kDa. Protein analysis
by Coomassie staining of the peak fraction after separation by
SDS-PAGE suggested a 1:1 ratio of Vif:CBFb140 (Fig. 4B). Full
length or truncated CBFb were monomeric in solution [78]. This
observation supports previous findings that Vif directly interacts
with CBFb [72]. Gel filtration analysis of purified Vif-CBFb140-
EloB/C revealed that the complex formed a homogeneous
complex of ,65–75 kDa (Fig. 4C). Protein analysis by Coomassie
staining of the peak fraction indicated a 1:1:1:1 ratio of
Vif:CBFb140:EloB:EloC (Fig. 4D) or Vif:CBFb187:EloB:EloC
(Fig. 4E). The calculated molecular weight of the monomeric Vif-
CBFb140-EloB/C complex (,65 kDa) was in close agreement
with our gel filtration results (,75 kDa) suggesting that Vif-CBFb-
EloB/C complex is a monomeric complex in solution.
The stability of the purified Vif-CBFb140 complexes was low: at
4uC, the complexes precipitated after only a few hours (Fig. 5B).
After 16 h at 4uC, .50% of the Vif protein precipitated (Fig. 5C,
lanes 1–3). More Vif protein than CBFb140 protein appeared in
the precipitates, although the initial ratio of Vif and CBFb was
about 1:1 (Fig. 5C, lane 1).In contrast, the Vif-CBFb140-EloB/C
complexes were more stable (Fig. 5A, lanes 4–6): only a trace
amount of Vif precipitated after 16 h at 4uC.
Previous studies have suggested that HIV-1 Vif can bind RNA
[79,80,81,82]. We found that the Vif-CBFb140-EloB/C complex-
es were resistant to RNase treatment (Fig. 5A). Purified Vif-
CBFb140-EloB/C complexes were untreated or treated with
40 mg/ml of RNase A and 20 U/ml RNase T1 at 37uC for 4 h.
After buffer exchange, the treated samples were purified using
nickel columns. RNase treatment did not affect the co-purification
of Vif, EloB, and EloC with CBFb140-His (Fig. 5A, lane 2) when
compared to the untreated sample (lane 1). These data suggest that
the Vif-CBFb-EloB/C complexes are not RNA-dependent. The
OD280/260 ratio in the peak fraction of the Vif-CBFb140 -EloB/
C complexes (Fig. 4C) also argued against the presence of RNA.
Interaction of CBFb with Vif truncation mutants
We next asked which region of Vif was required for the
interaction between Vif and CBFb. Two truncated Vif mutants
spanning residues 1–176 and 1–140 were constructed and co-
expressed with CBFb140-His. Truncated Vif in the soluble
fractions was analyzed by co-precipitation with CBFb140-His
using nickel beads. SDS-PAGE and Coomassie staining indicated
that both truncated Vif176 (Fig. 6A) and Vif140 (Fig. 6D) co-
precipitated with CBFB140-His; this finding was confirmed by
immunoblotting with a Vif- or CBFb-specific antibody (Fig. 6A
and D).The pulldown fractions were further analyzed by size
exclusion. Both Vif176-CBFb140 (Fig. 6B) and Vif140-CBFb140
(Fig. 6E) formed large aggregates. Peak fractions were analyzed by
SDS-PAGE followed by Coomassie staining. Both Vif176-
CBFb140 (Fig. 6C) and Vif140-CBFb140 (Fig. 6F) showed a 1:1
ratio of Vif:CBFb. These results suggested that N-terminal
residues 1–140 of HIV-1 Vif are sufficient for CBFb binding.
Vif-CBFb-EloB/C forms a complex with Cul5
Because binding to Cul5 is essential for Vif-mediated ubiqui-
tination and degradation of target proteins such as A3G and A3F,
we next determined whether these purified Vif-CBFb140-EloB/C
complexes could interact with Cul5. Vif-CBFb140-EloB/C
complexes and Cul5 NTD were purified separately (Fig. 7). The
purified Vif-CBFb-EloB/C complexes were mixed with purified
Figure 5. Vif-CBFb-EloB/C is an RNA-independent stable
complex in solution. (A) Vif-CBFb-EloB/C was not dependent on
RNA. The purified complex (2 mg/ml, 100 ml) was incubated with 2 ml
RNase Mix (RNase A/T1 Mix, Catalog EN055, Fermentas) at 37uC for 4 h
according to the manufacturer’s protocol, followed by buffer exchange
to remove the EDTA. The complex then was analyzed by His-tag affinity
pull-down. (B) The Vif-CBFb complex is not stable. Purified Vif-CBFb
complexes were concentrated to 4 mg/ml and, after clarification at
13,000 g for 10 min, the supernatants were stored at 4uC (Input).
Samples were then removed at different times (0 h, 6 h, 24 h), and after
clarification at 13,000 g for 10 min, the supernatants (S) were removed
and the pellets (P) resuspended to the original volume and checked by
SDS-PAGE. (C) Purified Vif complexes were concentrated to 5 mg/ml
(Input) and stored at 4uC overnight (,16 h). The supernatants (S) were
removed after clarification at 13,000 g for 10 min, and the pellets (P)
were resuspended to the original volume, then checked by SDS-PAGE.
doi:10.1371/journal.pone.0033495.g005
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compared to Vif-CBFb140-EloB/C (blue line) and Cul5 (cyan
line), the mixture (red line) had an earlier elution peak (Fig. 8A).
This result suggested that Vif-CBFb140-EloB/C may form a
complex with Cul5. SDS-PAGE analysis of the peak fractions
suggested that Cul5 and Vif-CBFb140-EloB/C formed a complex
(Fig. 8B, upper panel). Molecular weight analysis by gel filtration
(Fig. 8B, lower panel) indicated that the molecular size of the Vif-
CBFb140-EloB/C-Cul5 complex was approximately 135 kDa,
equal to the sum of Cul5 (,62 kDa) and Vif-CBFb140-EloB/C
(,75 kDa). Further analysis using affinity pull-down via His-
tagged CBFb confirmed the formation of Cul5-Vif-CBFb140-
EloB/C complexes (Fig. 8C). These Vif-CBFb140-EloB/C-Cul5
complexes were stable at 4uC over 16 h (Fig. 5C, lanes 7–9). The
interaction between Cul5 and Vif-CBFb-EloB/C suggests that
Vif-CBFb-EloB/C may be a functional complex, in vivo.
Discussion
Human CBFb has recently been identified as a critical regulator
of HIV-1 Vif function [72,73,74,75]. In the present study, we
demonstrate that this host regulator directly interacts with Vif
alone and in complex with E3 ligase components, in vitro. CBFb is
the non-DNA-binding subunit of a heterodimeric transcription
factor, including RUNX family proteins [83,84]. CBFb regulates
the folding and DNA-binding activity of RUNX partners, which
play important roles in the development and differentiation of
diverse cell types, including T lymphocytes and macrophages
[83,84]. We have recently reported that CBFb is critical for Vif-
induced A3G polyubiquitination and degradation [72]. Further
clarification of the Vif-CBFb-EloB/C-Cul5 interaction and
complex assembly would provide key insights into how Vif recruits
these E3 ligase components to degrade A3G/A3F.
Co-expression of HIV-1 Vif with CBFb in the absence of all
other human factors increased Vif solubility in E. coli. Soluble Vif
could be co-precipitated with both His-tagged full length or
truncated CBFb (Fig. 3C, D, and E) In the absence of binding
partners, previous research has suggested full length Vif appears to
be unstructured and poorly soluble, in vitro [85]. Recently, Wolfe et
al. were able to obtain soluble C-terminal domain fragments of Vif
in complex with EloB/C and Cul5 [63]. Attempts at character-
izing full length Vif in complex with EloB/C and Cul5 were
unsuccessful, suggesting that the N-terminus was responsible for
Vif’s poor solubility, in the absence of N-terminal binding
partners. We have shown that CBFb binds the N-terminal region
of Vif, specifically requiring hydrophobic interactions at amino
acids W21 and W38 [72]. We hypothesize that the exposure of the
N-terminal hydrophobic surface may contribute to Vif insolubilty
Figure 6. Vif140 and Vif176 bind to CBFb and form aggregated complexes. (A) and (D), Vif was co-expressed with CBFb. The supernatant
from the cell lysates was used as the input sample. Both input and pull-down samples were checked by SDS-PAGE, followed by Coomassie staining or
blotting. (B) and (E), The purified Vif- CBFb140 complexes were checked by gel filtration on a Superdex200 10/300 column. (C) and (F), The peak
factions were analyzed by SDS-PAGE and Coomassie staining.
doi:10.1371/journal.pone.0033495.g006
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Vif-Cul5 binding, though CBFb does not bind Cul5 directly
[72,73]. Thus, a possible role for CBFb would be to stabilize Vif
structure and promote the assembly of the Vif-Cul5 E3 ubiquitin
ligase complex.
Vif and CBFb co-fractionated in gel filtration analyses and
appeared as a 1:1 ratio complex. Isoforms 1 and 2 as well as a
truncated form (amino acids 1–140) of CBFb all interacted with
HIV-1 Vif. Thus, most, if not all, of the Vif binding activity is
preserved within the first 140 amino acids of CBFb. Of note, C-
terminal truncation of CBFb up to amino acids 1–135 have been
reported to bind and act in complex with RUNX family proteins
[86]. In addition, we have confirmed that CBFb binds to at least
the first 140 amino acids of HIV-1 Vif. Thus, the known protein-
binding domains in Vif, including the EloB/C binding BC-box,
the cullin box containing the PPLP motif, are not essential for the
Vif-CBFb interaction. Vif forms homo-oligomers, and the PPLP
motif has been suggested to be required for oligomerization
[63,70,87,88,89,90]. Since Vif140 still forms oligomers with
CBFb140, CBFb182, and CBFb187, our results suggest that
regions in Vif in addition to PPLP may also participate in Vif
oligomerization. This conclusion is consistent with the recent
finding that the PPLP motif is not sufficient for Vif multi-
merization [64].
Biophysical and structural information for Vif has been limited
as a result of its insolubility and strong tendency to oligomerize
into high molecular weight aggregates. Of note, previous
biochemical studies have employed full-length Vif protein
obtained by the denaturing/refolding method [90] or have used
truncated tagged protein [63]. Interestingly, when CBFb and
EloB/C were present, even untagged full-length Vif could be
purified as a stable and soluble complex.
Association of Vif with CBFb alone, and especially in
combination with EloB/C, greatly increases the solubility of full-
length Vif. We have shown that a stable complex containing Vif-
CBFb140-EloB/C can be purified in large quantities. This
complex appeared to contain one subunit of each protein and
did not dissociate upon RNase treatment. More importantly, the
Vif-CBFb140-EloB/C complexes we produced could interact with
purified Cul5 and form stable Vif-CBFb140-EloB/C-Cul5
complexes. This successful purification of monomeric Vif-E3
ligase complexes in high purity will greatly facilitate biochemical
studies, structural determination, and functional analyses in this
field.
Because CBFb is a unique regulator of Vif’s ability to hijack the
cellular CRL5 E3 ligase, disrupting interactions within the Vif-
CBFb140-EloB/C-Cul5 complex represents an exciting drug
strategy for targeting HIV-1. Inhibitors that prevent complex
formation would be potential candidates for HIV-1 suppression,
and purification of these Vif complexes in homogeneous form
would provide the basis for screens to identify and evaluate
inhibitor candidates. Thus, our strategy for purifying Vif-Cul5-
Figure 7. Purification strategy used in this study. IPTG, isopropyl-D-thiogalactopyranoside. Expression conditions are indicated, as are
the buffers and methods used in each step.
doi:10.1371/journal.pone.0033495.g007
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for identifying novel anti-HIV drug candidates.
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